Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities

Drug Metabolism and Disposition

Volumn 26, Issue 3, 1998, Pages 207-215

  Hickman, Dean ^a   Wang, Ji Ping ^c   Wang, Yi ^c   Unadkat, Jashvant D ^b  

^a ABBOTT LABORATORIES   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 NITROPHENOL; CAFFEINE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450 ISOENZYME; DEXTROMETHORPHAN; DIETHYLDITHIOCARBAMIC ACID; FURAFYLLINE; MEPHENYTOIN; METHOXSALEN; QUINIDINE; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN; UMBELLIFERONE; ZALCITABINE;

ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; LIVER MICROSOME METABOLISM; MICHAELIS CONSTANT; PRIORITY JOURNAL;

ACETONITRILES; CYTOCHROME P-450 ENZYME SYSTEM; DIMETHYLFORMAMIDE; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; SOLVENTS;

EID: 0031921010     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Berthou F, Goasduff T, Lucas D, Dreano Y, Le Bot M-H and Menez J-F (1995) Interaction between two probes used for phenotyping cytochromes P4501A2 (caffeine) and P4502E1 (chlorzoxazone) in humans. Pharmacogenetics 5:72-79.
2. 14C-methyl]caffeine. Xenobiotica 25:917-927.
3. Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS and Guengerich FP: (1989) Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28:4993-4999.
4. Broly F, Libersa C, Lhermitte M, Bechtel P and Dupuis B (1989) Effect of quinidine on the dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br J Clin Pharmacol 28:29-36.
5. Butler MA, Iwasaki M, Guengerich FP and Kadlubar FF (1989) Human cytochrome P-450PA (P-450IA2), the phenacetin O-demethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 86:7696-7700.
6. Campbell ME, Grant DM, Inaba T and Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 15:237-249.
7. Chang TKH, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
8. Chiba K, Manabe K, Kobayashi K, Takayama Y, Tani M and Ishizaki T (1993) Development and preliminary application of a simple assay of S-mephenytoin 4-hydroxylase activity in human liver microsomes. Eur J Clin Pharmacol 44:559-562.
9. 1 activity. Clin Pharmacol Ther 45:34-40.
10. Doecke CJ, Veronese ME, Pond SM, Miners JO, Birkett DJ, Sansom LN and McManus ME: (1991) Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol 31:125-130.
11. Fuhr U, Doehmer J, Battula N, Wolfel C, Kudla C, Keita Y and Staib AH (1992) Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. Biochem Pharmacol 43:225-235.
12. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM and Ghanayem BI (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33:1743-1752.
13. Gorski JC, Jones DR, Wrighton SA and Hall SD: (1994) Characterization of dextromethorphan N-demethylation by human liver microsomes: Contribution of the cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 48:173-182.
14. Gu L, Gonzalez FJ, Kalow W and Tang BK (1992) Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2. Pharmacogenetics 2:73-77.
15. Guengerich FP, Kim D-H and Iwasaki M (1991) Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 4:168-179.
16. Jacqz-Aigrain E, Funck-Brentano C and Cresteil T (1993) CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans. Pharmacogenetics 3:197-204.
17. Kunze KL and Trager WF (1993) Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furaphylline. Chem Res Toxicol 6:649-656.
18. Kupfer A, Schmid B and Pfaff G: (1986) Pharmacogenetics of dextromethorphan O-demethylation in man. Xenobiotica 16:421-433.
19. Maenpaa J, Sigusch H, Raunio H, Syngelma T, Vuorela P, Vuorela H and Pelkonen O (1993) Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem Pharmacol 45:1035-1042.
20. Maurice M, Emiliani S, Dalet-Beluche I, Derancourt J and Lange R (1991) Isolation and characterization of cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 200:511-517.
21. Mays DC, Camisa C, Cheney P, Pacula CM, Nawoot S and Gerber N (1987) Methoxypsoralen is a potent inhibitor of the metabolism of caffeine in humans. Clin Pharmacol Ther 42:621-626.
22. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA and Wolf CR (1990) Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylation activity. Biochem J 267:365-371.
23. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes: Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37:1137-1144.
24. Murray M (1987) Mechanisms of the inhibition of cytochrome P450-mediated drug oxidation by therapeutic agents. Drug Metab Rev 18:55-81.
25. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Nebert DW (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
26. Newton DJ, Wand RW and Lu AYH (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Disp 23:154-158.
27. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, and Gonzalez FJ: (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics 5:143-150.
28. Ono S, Hatanaka T, Hotta H, Satohi T, Gonzalez FJ and Tsutui M (1996) Specificity of substrate and inhibitor probes for cytochrome P450s: Evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
29. Palamada JR, Hickman D, Ward A, Sim E, Romkes-Sparkes M and Unadkat JD (1995) Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs. Drug Metab Disp 23:473-477.
30. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450 IIE1. Chem Res Toxicol 3:566-573.
31. Relling MV, Aoyama T, Gonzalez FJ and Meyer UA (1990) Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J Pharmacol Exp Ther 252:442-447.
32. Rettie AE, Eddy AC, Heimark LD, Gibaldi M and Trager WF (1989) Characteristics of warfarin hydroxylation catalyzed by human liver microsomes. Drug Metab Dispos 17:265-270.
33. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
34. Schmid B, Bircher J, Preisig R and Küpfer A (1985) Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation. Clin Pharmacol Ther 38:618-624.
35. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, De La Torre R and Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663.
36. Shimada T, Gillam EM, Sandhu P, Guo Z, Tukey RH and Guengerich FP (1994a) Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli: Simplified bacterial systems for genotoxicity assays. Carcinogenesis 15:2523-2529.
37. Shimada T, Ymazaki H, Mimura M, Inui Y and Guengerich FP (1994b) Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Ther 270:414-423.
38. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin HV and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
39. Srivastava PK, Yun C-H, Beaune PH, Ged C and Guengerich FP (1991) Separation of human liver microsomal tolbutamide hydroxylase and (S)-mephenytoin 4′-hydroxylase cytochrome P-450 enzymes. Mol Pharmacol 40:69-79.
40. Tassaneeyakul W, Mohamed Z, Birkett DJ, McManus ME, Veronese ME, Tukey RH, Quattrochi LC, Gonzalez and Miners JO (1992) Caffeine as a probe for human cytochrome P450: Validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2:173-183.
41. Tassaneeyakul W, Veronese ME, Birkett DJ, Gonzalez FJ and Miners JO (1993) Validation of 4-nitrophenol as an in vitro substrate probe for human liver CYP2E1 using cDNA expression and microsomal kinetic techniques. Biochem Pharmacol 46:1975-1981.
42. Tassaneeyakul W, Birkett DJ, McManus ME, Tassaneeyakul W, Veronese ME, Andersson T, Tukey RH and Miners JO (1994) Caffeine metabolism by human hepatic cytochromes P450: contribution of 1A2, 2E1 and 3A isoforms. Biochem Pharmacol 47:1767-1776.
43. Veronese ME, Miners JO, Randles D, Gregov D and Birkett DJ (1990) Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 47:403-411.
44. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DLP, Gasser R, Meyer UA and Birkett DJ (1993) Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:533-538.
45. Yamano S, Tatsuno J and Gonzalez FJ (1990) The Cyp2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322-1329.